Forever Green? An Examination of Pharmaceutical Patent Extensions

Loading...
Thumbnail Image

Date

2017-07-27

Authors

Marrs, Julian W.

Journal Title

Journal ISSN

Volume Title

Publisher

University of Oregon School of Law

Abstract

This Article examines Novartis in the context of pharmaceutical evergreening, and suggests that the U.S. intellectual property regime could be improved by adopting a provision similar to section 3(d). Part I discusses evergreening and the negative repercussions it has on both the U.S. patent system and society. Part II examines Novartis and the academic understanding of section 3(d)’s solution to evergreening. Part III briefly details the current state of pharmaceutical patent laws in the U.S. Finally, Part IV suggests what a similar provision in the U.S. system would look like.

Description

18 pages

Keywords

Patents, Pharmaceutical pricing, International law

Citation

18 Or. Rev. Int'l. L. 81 (2016)